RT Journal Article
T1 [Tolvaptan in a pediatric cardiorenal syndrome: What is its role?].
T2 Tolvaptán en un caso de síndrome cardiorrenal pediátrico: ¿Cuál es su papel?
A1 Tejero Hernández, M Angeles
A1 García Martínez, Elena
A1 Arroyo Marin, M José
A1 Gómez Guzmán, Elena
K1 Cardiorenal syndrome
K1 Child
K1 Tolvaptan
AB The cardiorenal syndrome has been defined as a situation in which therapy to relieve congestive symptoms of heart failure is limited by a decreased renal function. The resistance to conventional diuretic treatment makes difficult managing these patients. Tolvaptan, a selective vasopressin-2 receptor antagonist, has been used successfully in adults with this pathology but the experience with children is very limited. A five-year-old girl with renal failure waiting for a heart transplant is presented. Tolvaptan (0.1 mg/kg/day) was started at very low dosage, resulting in an excellent response. We analyzed the creatinine, urea, urine volume and sodium evolution. Renal function also improved. She could be discharged after four days of treatment (156 days of hospitalization) with ambulatory favourable follow-up until heart transplant. Tolvaptan should be considered in pediatric cases of conventional diuretic-resistant congestive heart failure, especially when complicated by kidney disease.
YR 2018
FD 2018
LK http://hdl.handle.net/10668/12254
UL http://hdl.handle.net/10668/12254
LA es
DS RISalud
RD Apr 14, 2025